PRQR ProQR Therapeutics N.V.

8.87
-0.08  -1%
Previous Close 8.95
Open 8.96
Price To Book 3.77
Market Cap 344,967,942
Shares 38,891,538
Volume 24,005
Short Ratio
Av. Daily Volume 194,007

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 data due YE 2020.
Sepofarsen (QR-110 ) ILLUMINATE
Leber's Congenital Amaurosis (LCA) - Genetic blindness
Phase 1b top-line data released September 25, 2017. FEV levels not significant across four doses. One of four doses showed significance in subgroup.
QR-010
Cystic Fibrosis
Phase 1/2 interim analysis announced March 26, 2019. Future development to be conducted by Wings Therapeutics.
QR-313
Epidermolysis bullosa
Phase 1/2 trial to be initiated 2019.
QR-1123
autosomal dominant retinitis pigmentosa (adRP)
Presentation of data made July 13, 2019.
QR-421a - STELLAR
Usher Syndrome Type 2

Latest News

  1. ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July
  2. Here’s What Hedge Funds Think About ProQR Therapeutics NV (PRQR)
  3. ProQR to Present at the JMP Securities Life Sciences Conference
  4. Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 153%?
  5. ProQR to Present at the RBC Capital Markets Healthcare Conference
  6. Here is What Hedge Funds Think About ProQR Therapeutics NV (PRQR)
  7. ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates
  8. ProQR: 1Q Earnings Snapshot
  9. ProQR Announces Financial Results for the First Quarter of 2019
  10. ProQR to Present at Three Scientific Conferences in April
  11. ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board
  12. ProQR Announces Annual Meeting of Shareholders
  13. ProQR Initiates Dosing in Phase II/III Eye Disorder Study
  14. ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
  15. ProQR to Present at the H.C. Wainwright Global Life Sciences Conference
  16. ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
  17. ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
  18. ProQR to Present at Cowen Health Care Conference
  19. Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus
  20. ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results